SOUTH SAN FRANCISCO, Calif., Feb. 16 /PRNewswire-FirstCall/ -- Renovis, Inc. will webcast its fourth quarter and full year 2005 conference call with the financial community, discussing operational and financial results and the company’s outlook for the future. The live webcast of this conference call will begin at 4:30 PM ET on Thursday, February 23, 2006.
A news release discussing Renovis’ third quarter 2005 financial results will be issued Thursday, February 23, 2006, after the market closes at 4:00 PM ET.
Interested parties may access the call by dialing 1-866-362-4666 in the United States and 1-617-597-5313 Internationally. The participant code is 99968301. This call is being webcast by CCBN and can be accessed in the Investor Relations section of Renovis’ web site at www.renovis.com. A replay of the webcast will be available until the time of the first quarter 2006 conference call, currently planned for April 27, 2006.
The webcast is also being distributed over CCBN’s Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN’s individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in CCBN’s Individual Investor Network. Institutional investors can access the call via CCBN’s password-protected event management site, StreetEvents (www.streetevents.com).
About Renovis
Renovis is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. Our most advanced product candidate, NXY-059, is in Phase III clinical trials for acute ischemic stroke with our exclusive licensee, AstraZeneca AB. NXY-059, an investigational drug under development by AstraZeneca and licensed from Renovis, has a proposed mechanism of action of free radical trapping. It is being studied as a neuroprotectant in clinical trials based on effects seen in experimental models of acute ischemic stroke. Our research and development programs focus on major medical needs in the areas of neuroprotection and pain. We have a worldwide collaboration and license agreement with Pfizer to research, develop and commercialize small molecule VR1 antagonists, and a research and development collaboration with Genentech to discover and develop anti-angiogenesis drugs and drugs that promote nerve re-growth following nervous system injury.
For additional information about the company, please visit www.renovis.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Renovis cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors, which could cause actual results or events to differ materially from the forward- looking statements that we make, are described in greater detail in the “Risk Factors” section of our Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 14, 2005. We do not assume any obligation to update any forward-looking statements.
Contacts: INVESTORS: MEDIA: Renovis, Inc. Noonan Russo John C. Doyle Jane Petrino (650) 266-1407 212-845-4274 doyle@renovis.comjane.petrino@eurorscg.com
Renovis, Inc.
CONTACT: INVESTORS: John C. Doyle, Renovis, Inc., +1-650-266-1407,doyle@renovis.com; MEDIA: Jane Petrino, Noonan Russo, +1-212-845-4274,jane.petrino@eurorscg.com, for Renovis, Inc.
Web site: http://www.renovis.com/
